BridgeBio Pharma, Inc. (BBIO)
Stock Price:
$39.53 USD
-1.44 (-3.51%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
4.84B |
| Revenue (ttm) |
40.56M |
| Net Income (ttm) |
-346.32M |
| Shares Out |
122.54M |
| EPS (ttm) |
-4.73 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$39.53 |
| Previous Close |
$40.97 |
| Change ($) |
-1.44 |
| Change (%) |
-3.51% |
| Day's Open |
41.26 |
| Day's Range |
38.75 - 41.49 |
| Day's Volume |
779,754 |
| 52-Week Range |
14.23 - 48.36 |
More Stats
| Market Cap |
4.84B |
| Enterprise Value |
4.48B |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
122.54M |
| Float |
74.20M |
| EPS (basic) |
-2.94 |
| EPS (diluted) |
-4.73 |
| FCF / Share |
-2.61 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
10.64M |
| Short Ratio |
14.12 |
| Short % of Float |
14.35% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
119.43 |
| PB Ratio |
18.89 |
| Revenue |
40.56M |
| Operating Income |
-360.22M |
| Net Income |
-346.32M |
| Free Cash Flow |
-304.77M |
| Net Cash |
361.64M |
| Net Cash / Share |
2.95 |
| Gross Margin |
93.84% |
| Operating Margin |
-888.13% |
| Profit Margin |
-853.90% |
| FCF Margin |
-751.41% |
| ROA |
-36.59% |
| ROE |
-145.59% |
| ROIC |
-66.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (9)
| Buy |
7 |
| Overweight |
1 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$46.78*
(18.34% upside)
Low
39.0
Current: $39.53
High
53.0
Target: 46.78
*Average 12-month price target from 9 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 40.56 | - | - |
| Gross Profit | 38.06 | - | - |
| Operating Income | -266 | -184 | -43.86 |
| Net Income | -261 | -131 | -30.57 |
| Shares Outstanding | 105 | 61.77 | 30.60 |
| Earnings Per Share | -2.48 | -2.12 | -1.00 |
| Operating Cash Flow | -254 | -137 | -40.49 |
| Capital Expenditures | -2.64 | -2.18 | -0.46 |
| Free Cash Flow | -256 | -139 | -40.95 |
| Cash & Equivalents | 546 | 436 | 92.00 |
| Total Debt | 91.79 | 54.51 | - |
| Net Cash / Debt | 454 | 382 | 92.00 |
| Assets | 632 | 465 | 98.04 |
| Liabilities | 156 | 87.58 | 8.86 |
| Book Value | 408 | 315 | -61.43 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
BridgeBio Pharma, Inc. |
| Country |
United States |
| Employees |
328 |
| CEO |
Neil Kumar |
Stock Information
| Ticker Symbol |
BBIO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: BBIO |
| IPO Date |
June 27, 2019 |
Description
BridgeBio Pharma engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; and strategic collaboration agreements with Johns Hopkins University and University of Florida. The company was founded in 2015 and is headquartered in Palo Alto, California.